These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 10913332

  • 1. Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria.
    O'Brien EA, Williams JH, Marshall MJ.
    Biochem Biophys Res Commun; 2000 Aug 02; 274(2):281-90. PubMed ID: 10913332
    [Abstract] [Full Text] [Related]

  • 2. Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane.
    O'Brien EA, Williams JH, Marshall MJ.
    Bone; 2001 Feb 02; 28(2):208-14. PubMed ID: 11182380
    [Abstract] [Full Text] [Related]

  • 3. Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii.
    Choi BK, Moon SY, Cha JH, Kim KW, Yoo YJ.
    J Periodontol; 2005 May 02; 76(5):813-20. PubMed ID: 15898943
    [Abstract] [Full Text] [Related]

  • 4. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
    Palmqvist P, Persson E, Conaway HH, Lerner UH.
    J Immunol; 2002 Sep 15; 169(6):3353-62. PubMed ID: 12218157
    [Abstract] [Full Text] [Related]

  • 5. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis.
    Tsurukai T, Udagawa N, Matsuzaki K, Takahashi N, Suda T.
    J Bone Miner Metab; 2000 Sep 15; 18(4):177-84. PubMed ID: 10874596
    [Abstract] [Full Text] [Related]

  • 6. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
    Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL.
    J Cell Biol; 1999 May 03; 145(3):527-38. PubMed ID: 10225954
    [Abstract] [Full Text] [Related]

  • 7. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.
    Huang L, Xu J, Wood DJ, Zheng MH.
    Am J Pathol; 2000 Mar 03; 156(3):761-7. PubMed ID: 10702390
    [Abstract] [Full Text] [Related]

  • 8. Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption in vitro.
    Tomita M, Li X, Okada Y, Woodiel FN, Young RN, Pilbeam CC, Raisz LG.
    Bone; 2002 Jan 03; 30(1):159-63. PubMed ID: 11792579
    [Abstract] [Full Text] [Related]

  • 9. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
    Shalhoub V, Faust J, Boyle WJ, Dunstan CR, Kelley M, Kaufman S, Scully S, Van G, Lacey DL.
    J Cell Biochem; 1999 Feb 01; 72(2):251-61. PubMed ID: 10022507
    [Abstract] [Full Text] [Related]

  • 10. Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin.
    Mancini L, Moradi-Bidhendi N, Brandi ML, Perretti M, MacIntyre I.
    Biochem Biophys Res Commun; 2000 Dec 20; 279(2):391-7. PubMed ID: 11118297
    [Abstract] [Full Text] [Related]

  • 11. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
    Atkins GJ, Kostakis P, Welldon KJ, Vincent C, Findlay DM, Zannettino AC.
    J Cell Physiol; 2005 Jun 20; 203(3):573-82. PubMed ID: 15573398
    [Abstract] [Full Text] [Related]

  • 12. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
    Michigami T, Ihara-Watanabe M, Yamazaki M, Ozono K.
    Cancer Res; 2001 Feb 15; 61(4):1637-44. PubMed ID: 11245477
    [Abstract] [Full Text] [Related]

  • 13. Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor beta and osteoprotegerin expression.
    Kobayashi Y, Hashimoto F, Miyamoto H, Kanaoka K, Miyazaki-Kawashita Y, Nakashima T, Shibata M, Kobayashi K, Kato Y, Sakai H.
    J Bone Miner Res; 2000 Oct 15; 15(10):1924-34. PubMed ID: 11028444
    [Abstract] [Full Text] [Related]

  • 14. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
    Lee SK, Lorenzo JA.
    Endocrinology; 1999 Aug 15; 140(8):3552-61. PubMed ID: 10433211
    [Abstract] [Full Text] [Related]

  • 15. Integrin subunit beta3 plays a crucial role in the movement of osteoclasts from the periosteum to the bone surface.
    Holt I, Marshall MJ.
    J Cell Physiol; 1998 Apr 15; 175(1):1-9. PubMed ID: 9491775
    [Abstract] [Full Text] [Related]

  • 16. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
    Kanatani M, Sugimoto T, Kano J, Kanzawa M, Chihara K.
    J Cell Physiol; 2003 Jul 15; 196(1):180-9. PubMed ID: 12767054
    [Abstract] [Full Text] [Related]

  • 17. Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages.
    Itonaga I, Sabokbar A, Murray DW, Athanasou NA.
    Ann Rheum Dis; 2000 Jan 15; 59(1):26-31. PubMed ID: 10627423
    [Abstract] [Full Text] [Related]

  • 18. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.
    Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ.
    Am J Pathol; 2000 Aug 15; 157(2):435-48. PubMed ID: 10934148
    [Abstract] [Full Text] [Related]

  • 19. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
    Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T.
    Endocrinology; 2000 Sep 15; 141(9):3478-84. PubMed ID: 10965921
    [Abstract] [Full Text] [Related]

  • 20. Critical role of beta3 integrin in experimental postmenopausal osteoporosis.
    Zhao H, Kitaura H, Sands MS, Ross FP, Teitelbaum SL, Novack DV.
    J Bone Miner Res; 2005 Dec 15; 20(12):2116-23. PubMed ID: 16294265
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.